	FORM 591M PART 1		U.S. NUCLEAR REGULATORY COMMISSION					
10 CFR 2.201 SAFETY INSPECTION REPORT AND COMPLIANCE INSPECTION								
1. L	CENSEE/LOCATION INSPECTED		2. NRC/REGIONAL OFFICE					
Bee	be Medical Center		Region 1					
424 Savannah Road			475 Allendale Rd					
Lewes, DE 19958			Suite 102 King of Prussia, PA 19406					
			King of Flussia, FA 13400					
		T						
3. DOCKET NUMBER(S)		4. LICENSE NUMBER(S)		5. DATE(S) OF INSPECTION				
030-13331		07-17792-01	08/15/2022					
LICENSEE: The inspection was an examination of the activities conducted under your license as they relate to radiation safety and to compliance with the Nuclear Regulatory Commission (NRC) rules and regulations and the conditions of your license. The inspection consisted of selective examinations of procedures and representative records, interviews with personnel, and observations by the inspector. The inspection findings are as follows: 1. Based on the inspection findings, no violations were identified.								
N	2. Previous violation(s) closed.							
	3. The violations(s), specifically described to you by the inspector as non-cited violations, are not being cited because they were self-identified, non-repetitive, and corrective action was or is being taken, and the remaining criteria in the NRC Enforcement Policy, to exercise discretion, were satisfied.							
	Non-cited violation(s) were discussed involving the following requirement(s):							
	10 CFR 20.1501, in part, requires each licensee shall make or cause to be made, surveys of areas, including the subsurface, that are reasonable under the circumstances to evaluate concentrations or quantities of residual radioactivity. Contrary to the above, between June 22, 2022 and August 3, 2022 the licensee didn't make or cause to be made, surveys of areas, including the subsurface, that are reasonable under the circumstances to evaluate concentrations or quantities of residual radioactivity. Contrary to the above, between June 22, 2022 and August 3, 2022 the licensee didn't make or cause to be made, surveys of areas, including the subsurface, that are reasonable under the circumstances to evaluate concentrations or quantities of residual radioactivity. Specifically, the licensee did not conduct surveys of the surgical areas where lymphoscintigraphy administrations of Tc99m were performed.							
	This is a SLIV in accordance with Section 6.3 of the NRC Enforcement Policy.							
	Corrective actions included staff education regarding surveys.							
$\mathbf{\nabla}$	4. During this inspection, certain of your activities, as described below and/or attached, were in violation of NRC requirements and are being cited in accordance with the NRC Enforcement Policy. This form is a NOTICE OF VIOLATION, which may be subject to posting in accordance with 10 CFR 19.11. (Violations and Corrective Actions)							
	10 CFR 35.27, in part, requires a licensee to instruct the supervised individual in the licensee's written radiation protection procedures, written directive procedures, regulations of this chapter, and license conditions with respect to the use of byproduct material. Contrary to the above, as of June 22, 2022 the licensee did not instruct the supervised individual in the licensee's written radiation protection procedures, written directive procedures, regulations of this chapter, and license conditions with respect to the use of byproduct material. Specifically, surgical staff performing lymphoscintigraphy procedures had not received training in the licensee's written radiation protection procedures, written directive procedures, regulations of this chapter, and license conditions with respect to the use of byproduct material.							
	This is a SLIV in accordance with Section 6.3 of the NRC Enforcement Policy.							
	Corrective actions include implementation of a training program for surgical staff operating under the supervision of an Authorized User. Training was completed by September 30, 2022.							
	fall within the prescribed dosage range of between January 1, 2021 and March 24, not fall within the prescribed dosage rang 5.6mCi, and 5.2mCi of Tc99m MAA was a	r if the dosage differs from the pre 2022 without being otherwise dire ge or the dosage differed from the administered for lung perfusion stu e of 1-5mCi. Similarly, on March 2	escribed dosage by more ected by the authorized u prescribed dosage by mo udies on January 1, 2021	r not use a dosage if the dosage does not than 20 percent. Contrary to the above, ser, the licensee used a dosage that did ore than 20 percent. Specifically, 5.5mCi, , January 11, 2021, and March 24, 2022, n Mebrofenin was administered for a HIDA				
	This is a SLIV in accordance with Section 6.3 of the NRC Enforcement Policy.							
	Corrective actions include establishment of a new dosage range and staff education on the new dosage range.							

NRC FORM 591M PART 1 (07-2012)				U.S. NUCLEAR REGULATORY COMMISSION						
10 CFR 2.201 SAFETY INSPECTION REPORT AND COMPLIANCE INSPECTION										
1. LICENSEE/LOCATION	N INSPECTED		2. NRC/REGIONAL OFFICE							
Beebe Medical Center 424 Savannah Road Lewes, DE 19958			Region 1 475 Allendale Rd Suite 102 King of Prussia, PA 19406							
REPORT NUMBER(s) 2022001										
3. DOCKET NUMBER(S)			5. DATE(S) OF INSPECTION							
030-13331 07-17		07-17792-01		08/15/2022						
corrective actions is made in	accordance with the	Statement of Cor escribed by me to the Inspector w e requirements of 10 CFR 2.201 and that no further written respon	vill be taken to correct the (corrective steps already	taken, corrective steps which	will be taken, date					
TITLE	P		SIG	NATURE	DATE					
LICENSEE'S REPRESENTATIVE	Dan Mapes		Dalp	my	10/13/22					
	Patrick-John I		Patrick-John E. H	Digitally signed by Patrick-John E. ANN Hann Date: 2022.10.12 13:32:41 -04'00'						
BRANCH CHIEF	Anne DeFran	cisco	Anne E. DeFr	ancisco Digitally signed by Anne Date: 2022.10.12 11:00:12	1. DeFrancisco 2-04'00'					
NRC FORM 591M PART 1 /07/201	2)				Page 2 of					